VSTRIP® COVID-19 ANTIGEN RAPID TEST APPROVED BY TAIWAN FDA
On August 27th, Taiwan FDA announced its approval of Vstrip® COVID-19 Antigen Rapid Test under Emergency Use Authorization (EUA).
This marks the FIRST antigen rapid test to be approved by Taiwan FDA for the detection of SARS-CoV-2 (COVID-19 virus). Vstrip® will continue to apply for approval from other international regulatory agencies including U.S. FDA (EUA), EU CE certification, and Japan PMDA.
Co-developed by Antaimmu BioMed, EirGenix, & Panion & BF Biotech (AEP Alliance), Vstrip® is a qualitative immunochromatographic assay that detects the presence of SARS-COV-2 antigens in nasopharyngeal swab samples. As viral antigen levels in the nasopharyngeal cavity rise quickly after infection, Vstrip® is highly effective for detection of early stage infections, including asymptomatic cases. Vstrip®’s simple point-of-care design requires no specialized equipment and can used easily, both in personal and professional settings. Quick, reliable results can be provided in only 10 minutes.